Osteosarkom Hücre Hattında Hedefe Spesifik RANKL İnhibitörü Olarak Gambojik Asidin Antikanser Profili

Yıl 2021, , 442 - 452, 31.08.2021

Aykut Özgür , Esra Duman

https://doi.org/10.18185/erzifbed.928668

Öz

Osteosarkom, genç nüfus arasında yaygın bir kanser türüdür ve genellikle büyüyen kemiklerde gelişir. Osteosarkom vakalarının yaklaşık yüzde yirmisi metastaz eğilimi gösterir ve osteosarkomlu hastaların tedaviden sonra hayatta kalma oranı düşüktür. Kemiğin yeniden şekillenmesinin RANK / RANKL / OPG anahtar düzenleyici üçlüsü, osteosarkomun tümör oluşumunda kritik rol oynar. Gambojik asidin anti-proliferatif aktivitesi, XTT testi ile Saos-2 hücre hattında belirlendi. Gambojik asidin antikanser aktivitelerini anlamak için RANK-RANKL kompleksi ile moleküler docking hesaplamaları da yapıldı. RANKL ve OPG'nin ekspresyon seviyeleri, RT-PCR ve ELISA deneyleri ile gen ve protein seviyesinde ölçüldü. Osteosarkom hücrelerine karşı in vitro potansiyel anti-invazif özelliği, yara iyileştirme deneyi kullanılarak değerlendirildi. Deneysel analizler, gambojik asidin Saos-2 hücrelerinde hücre proliferasyonunu, hücre göçünü ve RANKL / OPG'nin protein ekspresyon oranını azalttığını gösterdi. Gambogic asit, 549.38 nM'lik Kd değeri ve -8.54 kcal / mol'lük tahmini serbest enerji ile RANK-RANKL kompleksine bağlandı. Gambojik asidin, hedefe özgü osteosarkom tedavisi için önemli ilaç şablonu olduğu bulunmuştur.

Anahtar Kelimeler

Osteosarkom, Saos-2, Gambojik asit, RANK, RANKL, OPG

Destekleyen Kurum

Tokat Gaziosmanpaşa University

Proje Numarası

2019/86

Anticancer Profiling of Gambogic Acid as a Target Specific RANKL Inhibitor in Osteosarcoma Cell Line

Öz

Osteosarcoma is a common cancer type among the youth population and usually develops in growing bones. Approximately twenty percent of osteosarcoma cases show tendency to metastases and patients with osteosarcoma have a low survival rate after treatment. RANK/RANKL/OPG key regulator triad of bone remodeling play critical roles in tumourigenesis of osteosarcoma. Anti-proliferative activity of the gambogic acid was determined in Saos-2 cell line by XTT assay. To understand the anticancer activities of the gambogic acid, molecular docking calculations were also performed with RANK-RANKL complex. The expression levels of the RANKL and OPG was measured at gene and protein level with RT-PCR and ELISA assays. Its potential anti-invasive property in-vitro against osteosarcoma cells was evaluated using wound healing assay. Experimental assays indicated that gambogic acid suppressed cell proliferation, cell migration, and decreased protein expression ratio of RANKL/OPG in Saos-2 cells. Gambogic acid binds to RANK-RANKL complex with Kd value of 549.38 nM and with estimated free energy of binding -8.54 kcal/mol. Gambogic acid is found to be significant drug template for target specific osteosarcoma treatment.

Anahtar Kelimeler

Osteosarcoma, Saos-2, Gambogic acid, RANK, RANKL, OPG

Proje Numarası

2019/86

Kaynakça

• Ando, K., Mori, K., Rédini, F., Heymann, D. (2008). RANKL/RANK/OPG: key therapeutic target in bone oncology. Current Drug Discovery Technologies,5, 263-268.
• Baud'huin, M., Duplomb, L., Ruiz Velasco, C., Fortun, Y., Heymann, D., Padrines, M. (2007). Key roles of the OPG-RANK-RANKL system in bone oncology. Expert Review of Anticancer Therapy, 7, 221-232.
• Boyce, B.F., Xing, L. (2007). The RANKL/RANK/OPG pathway. Current Osteoporosis Reports, 5, 98-104.
• Boyce, B.F., Xing, L. (2009). Functions of RANKL/RANK/OPG in bone modeling and remodeling. Archives of Biochemistry and Biophysics, 473, 139-146.
• Branstetter, D., Rohrbach, K., Huang, L.Y., Soriano, R., Tometsko, M., Blake, M., Jacob, A.P., Dougall, W.C. (2015). RANK and RANK ligand expression in primary human osteosarcoma. Journal of Bone Oncology, 4, 59-68.
• Chi, Y., Zhan, X.K., Yu, H., Xie, G.R., Wang, Z.Z., Xiao, W., Wang, Y.G., Xiong, F.X., Hu, J.F., Yang, L., Cui, C.X., Wang, J.W. (2013). An open-labeled, randomized, multicenter phase IIa study of gambogic acid injection for advanced malignant tumors. Chinese Medical Journal, 126, 1642-1646.
• Ganguly, K.K., Pal, S., Moulik, S., Chatterjee, A. (2013). Integrins and metastasis. Cell Adhesion & Migration, 7, 251-261.
• Gümus, M., Ozgur, A., Tutar, L., Disli, A., Koca, I., Tutar, Y. (2016). Design, Synthesis, and Evaluation of Heat Shock Protein 90 Inhibitors in Human Breast Cancer and Its Metastasis. Current Pharmaceutical Biotechnology, 17, 1231-1245.
• Hameed, M., Mandelker, D. (2018). Tumor Syndromes Predisposing to Osteosarcoma. Advances in Anatomic Pathology, 25, 217-222.
• Huang X, Zhao J, Bai J, Shen H, Zhang B, Deng L, Sun, C., Liu, Y., Zhang, J., Zheng, J. (2019). Risk and clinicopathological features of osteosarcoma metastasis to the lung: A population-based study. Journal of Bone Oncology,16, 100230.
• Huang, J., Bi, W., Han, G., Jia, J., Xu, M., Wang, W. (2018). The multidisciplinary treatment of osteosarcoma of the proximal tibia: a retrospective study. BMC Musculoskeletal Disorders,19, 315.
• Ishaq, M., Khan, M.A., Sharma, K., Sharma, G., Dutta, R.K., Majumdar, S. (2014). Gambogic acid induced oxidative stress dependent caspase activation regulates both apoptosis and autophagy by targeting various key molecules (NF-κB, Beclin-1, p62 and NBR1) in human bladder cancer cells. Biochimica et Biophysica Acta, 1840, 3374-3384.
• Kashyap, D., Mondal, R., Tuli, H.S., Kumar, G., Sharma, A.K. (2016). Molecular targets of gambogic acid in cancer: recent trends and advancements. Tumor Biology, 37, 12915-12925.
• Koca, İ., Gümüş, M., Özgür, A., Dişli, A., Tutar, Y. (2015). A Novel Approach to Inhibit Heat Shock Response as Anticancer Strategy by Coumarine Compounds Containing Thiazole Skeleton. Anti-Cancer Agents in Medicinal Chemistry, 15, 916-930.
• Liu, Y., Chen, Y., Lin, L., Li, H. (2020). Gambogic Acid as a Candidate for Cancer Therapy: A Review. International Journal of Nanomedicine, 15, 10385-10399.
• Misaghi, A., Goldin, A., Awad, M., Kulidjian, A.A. (2018). Osteosarcoma: a comprehensive review. SICOT J, 4, 12.
• Nie, F., Zhang, X., Qi, Q., Yang, L., Yang, Y., Liu, W., Lu, N., Wu, Z., You, Q., Guo, Q. (2009). Reactive oxygen species accumulation contributes to gambogic acid-induced apoptosis in human hepatoma SMMC-7721 cells. Toxicology, 260, 60-67.
• Ono, T., Hayashi, M., Sasaki, F., Nakashima, T. (2020). RANKL biology: bone metabolism, the immune system, and beyond. Inflammation and Regeneration, 40, 2.
• Ottaviani, G., Jaffe, N. (2009). The epidemiology of osteosarcoma. Cancer Treatment and Research, 152, 3-13.
• Peng, X., Guo, W., Ren, T., Lou, Z., Lu, X., Zhang, S., Lu, Q., Sun, Y. (2013). Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer. PLoS One, 8: e58361.
• Shweikeh F, Bukavina L, Saeed K, Sarkis R, Suneja A, Sweiss F, Drazin, D. (2014). Brain Metastasis in Bone and Soft Tissue Cancers: A Review of Incidence, Interventions, and Outcomes. Sarcoma, 2014, 475175.
• Trinidad, E.M,, González-Suárez, E. (2016). RANKL inhibitors for osteosarcoma treatment: hope and caution. Annals of Translational Medicine, 4, 534.
• Wang, H., Zhao, Z., Lei, S., Li, S., Xiang, Z., Wang, X., Huang, X., Xia, G., Huang, X. (2019). Gambogic acid induces autophagy and combines synergistically with chloroquine to suppress pancreatic cancer by increasing the accumulation of reactive oxygen species. Cancer Cell International,19, 7.
• Wang, X., Chen, W. (2012). Gambogic acid is a novel anti-cancer agent that inhibits cell proliferation, angiogenesis and metastasis. Anti-Cancer Agents in Medicinal Chemistry,12, 994-1000.
• Wang, X., Zheng, H., Shou, T., Tang, C., Miao, K., Wang, P. (2017). Effectiveness of multi-drug regimen chemotherapy treatment in osteosarcoma patients: a network meta-analysis of randomized controlled trials. Journal of Orthopaedic Surgery and Research,12, 52.
• Wen, C., Huang, L., Chen, J., Lin, M., Li, W., Lu, B., Rutnam, Z.J., Iwamoto, A., Wang, Z., Yang, X., Liu, H. (2015) Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells. International Journal of Oncology,47, 1663-1671.
• Xin, Z.F., Shen, C.C., Tao, L.J., Yan, S.G., Wu, H.B. (2013). Gambogic acid inhibits invasion of osteosarcoma via upregulation of TIMP-1. International Journal of Molecular Medicine, 31, 105-112.
• Xu, B., Ding, J., Chen, K.X., Miao, Z.H., Huang, H., Liu, H., Luo, X.M. (2012). Advances in Cancer Chemotherapeutic Drug Research in China. Recent Advances in Cancer Research and Therapy, 287–350.
• Zhou, Z., Ma, J. (2019). Gambogic acid suppresses colon cancer cell activity in vitro. Experimental and Therapeutic Medicine, 18, 2917-2923.